Class Iii Or Iv Lupus Nephritis With Active Disease Therapeutics
1. Lupkynis patent expiration
Treatment: Treatment of patients with active lupus nephritis
LUPKYNIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7332472 | AURINIA | Cyclosporine analogue mixtures and their use as immunomodulating agents |
Jan, 2026
(8 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11622991 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(11 years from now) | |
| US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 22 January, 2025
Market Authorisation Date: 22 January, 2021
Dosage: CAPSULE
More Information on Dosage
LUPKYNIS family patents
